Processa Pharmaceuticals Inc (PCSA) Stock Price, Quote & News

Company Profile

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical t...

Industry: Biotechnology

Sector: Healthcare

Phone: 443 776 3133

Fax: 443 288 4420

Website: www.processapharmaceuticals.com

Address:

7380 Coca Cola Drive, Suite 106, Hanover, United States

TheDrunkTrader69 Sep. 9 at 8:48 PM

$PCSA Hmmm dead all day an now AH movement

0 · Reply

TheDrunkTrader69 Sep. 9 at 4:00 PM

$PCSA Someone has same thoughts as me buys at .175 just had small add to even out lol.

0 · Reply

Paraplego Sep. 8 at 8:34 PM

$PCSA This is what we have by end of year 1. H2 2025: Interim analysis of Phase 2 trial for NGC-Cap in metastatic breast cancer (September is mentioned as possible month ) 2. H2 2025: FDA discussion regarding Phase III design for PCS499 in rare kidney diseases 3. Potential Partnership Developments: Further progress in licensing and partnership discussions for non-core assets 4. Continued Enrollment: Progress in patient recruitment for ongoing Phase 2 trial .

0 · Reply

TheDrunkTrader69 Sep. 8 at 8:01 PM

$PCSA This is far from dead and once shorts start getting pummeled you will see this can go from .17 to $1 very quickly .

2 · Reply

Paraplego Sep. 8 at 7:57 PM

$PCSA this is one of those negative people who was talking how pcsa is dead etc doing everything to puah stock value down

0 · Reply

Paraplego Sep. 8 at 7:13 PM

$PCSA i would like to know who is doing this

0 · Reply

jhidle0415 Sep. 8 at 4:19 PM

$PCSA 6th voicemail transcript from them in 5 days as i just stopped answering… 16314985583 Deposited a new message: "Hello, this is Wendy Guy, Chief administrative Officer Professor Pharmaceuticals. I'm reaching out regarding our 2025 special meeting. It has been adjourned from September 2nd. And moved to September 12, 2025 due to limited shareholder participation. Your vote is critical to reaching the required 33% quorum, and the board recommends voting for on all proposals. Every vote counts no matter how many shares you hold. We just appreciate your vote whether you vote yes, no, or abstain. If you have any questions or need help voting, please contact our proxy solicitor Laurel Hill at 888-742-1305. Again, that number is 888-742-1305. As always, thank you again for your continued support of Professor Pharmaceuticals. Thank you and have a great day." Click here: 14699825011 to listen to full voice message.

1 · Reply

red619 Sep. 8 at 1:11 PM

$PCSA pre market is being goofy 0.o

1 · Reply

TheDrunkTrader69 Sep. 8 at 12:47 PM

$PCSA One more thought for the day, when this starts moving up rember stop loss, it might pop then drop again. Its gonna pop just just dont know when or how high but be ready. Dont think im right dont listen to me. This is my opinion, use your best judgement.

1 · Reply

TheDrunkTrader69 Sep. 8 at 12:14 PM

$PCSA My thoughts are investors want in but playing the game to get in cheap, RS would suite them fine, but hurt us, if no RS we will see whales come in and fast, .17 to $1 IMO, no guarantees but seen it before right before a delist scare, OTC is better then RS, the structure is there company is strong. No reason to be down here, also bears want RS so dont listen to their crap either.

1 · Reply

Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies

Jul 1, 2025, 9:00 AM EDT - 2 months ago

Processa Pharmaceuticals Provides Portfolio and Business Update

Jun 17, 2025, 12:26 PM EDT - 3 months ago

Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering

Jun 17, 2025, 9:00 AM EDT - 3 months ago

Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate

Jun 13, 2025, 8:00 AM EDT - 3 months ago

Processa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025

May 30, 2025, 9:00 AM EDT - 3 months ago

Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting

Apr 15, 2025, 8:00 AM EDT - 5 months ago

Processa Pharmaceuticals' Dr. David Young to Present at World Orphan Drug Congress USA 2025

Mar 18, 2025, 8:30 AM EDT - 6 months ago

Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference

Feb 7, 2025, 8:00 AM EST - 7 months ago

Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference

Jan 30, 2025, 5:17 PM EST - 7 months ago

Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Jan 27, 2025, 8:30 PM EST - 8 months ago

Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Oct 2, 2024, 4:05 PM EDT - 1 year ago

Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer

Sep 3, 2024, 8:00 AM EDT - 1 year ago

Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September

Jun 11, 2024, 8:20 AM EDT - 1 year ago

Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer

May 6, 2024, 8:00 AM EDT - 1 year ago

Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference

Apr 30, 2024, 8:00 AM EDT - 1 year ago

Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research

Mar 25, 2024, 8:15 AM EDT - 1 year ago

Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting

Feb 21, 2024, 8:15 AM EST - 1 year ago

Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

Feb 14, 2024, 1:00 PM EST - 1 year ago

Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference

Feb 6, 2024, 8:30 AM EST - 1 year ago

Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

Feb 1, 2024, 4:22 PM EST - 1 year ago

Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering

Jan 26, 2024, 9:04 AM EST - 1 year ago

Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering

Jan 25, 2024, 11:29 AM EST - 1 year ago

What made Processa Pharmaceuticals stock nearly triple on Thursday?

Jan 25, 2024, 8:30 AM EST - 1 year ago

Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses

Jan 19, 2024, 7:45 AM EST - 1 year ago

Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer

Jan 18, 2024, 7:45 AM EST - 1 year ago

Processa Pharmaceuticals to Effect a 1-for-20 Reverse Stock Split

Jan 2, 2024, 5:06 PM EST - 1 year ago

Processa Pharmaceuticals to Present at the Biotech Showcase 2024

Dec 19, 2023, 9:00 AM EST - 1 year ago

Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over Capecitabine

Dec 13, 2023, 9:00 AM EST - 1 year ago

Processa Pharmaceuticals Announces Successful Phase 2 Meeting with FDA for Next Generation Capecitabine

Nov 30, 2023, 8:15 AM EST - 1 year ago

Processa Pharmaceuticals to Present at the MedInvest Oncology Investor Conference

Nov 29, 2023, 8:15 AM EST - 1 year ago

Processa Pharmaceuticals Issues Letter to Shareholders Highlighting Corporate Strategy, Drug Pipeline, and Outlook

Nov 13, 2023, 1:40 PM EST - 1 year ago

Processa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil Thompson

Nov 9, 2023, 8:15 AM EST - 1 year ago

Processa Pharmaceuticals to Present at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 Americas

Nov 1, 2023, 8:15 AM EDT - 2 years ago

Processa Pharmaceuticals Announces Formation of Oncology Advisory Board with Renowned Key Opinion Leaders

Oct 13, 2023, 1:08 PM EDT - 2 years ago

Processa Pharmaceuticals to Present at the ThinkEquity Conference

Sep 6, 2023, 8:15 AM EDT - 2 years ago

Processa Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 17, 2023, 8:05 AM EDT - 2 years ago

Processa Pharmaceuticals Provides Data Update Supporting a Potential Personalized Treatment Approach for Improved Cancer Care

Aug 10, 2023, 4:15 PM EDT - 2 years ago

Processa Pharmaceuticals to Present at the Sidoti & Co. Micro Cap Virtual Conference

Aug 8, 2023, 8:15 AM EDT - 2 years ago

Processa Pharmaceuticals Appoints Life Sciences Industry Veteran George Ng as Chief Executive Officer

Jun 14, 2023, 4:15 PM EDT - 2 years ago

Next Generation Chemotherapy: Improved Treatment for More Patients

May 22, 2023, 8:05 AM EDT - 2 years ago

Processa Pharmaceuticals to Participate in a Panel on Interaction with the FDA at the World Orphan Drug Congress

May 18, 2023, 8:00 AM EDT - 2 years ago

Processa Pharmaceuticals to Conduct Next Generation Chemotherapy-Capecitabine Phase 2 Trial Based on FDA Guidance and Project Optimus Oncology Initiative

Apr 28, 2023, 8:15 AM EDT - 2 years ago

Processa Pharmaceuticals to Present PCS12852 Gastroparesis Results at the Digestive Disease Week 2023 Annual Meeting

Mar 31, 2023, 4:14 PM EDT - 2 years ago

Processa Pharmaceuticals, Inc. (PCSA) Q4 2022 Earnings Call Transcript

Mar 30, 2023, 4:01 PM EDT - 2 years ago

Processa Pharmaceuticals Provides Corporate Update and Announces Year End 2022 Financial Results

Mar 23, 2023, 8:30 AM EDT - 2 years ago

Processa Pharmaceuticals to Host Conference Call to Discuss 2022 Year End Results and Provide Drug Development Update on March 30, 2023 at 4:30 p.m. EST

Mar 17, 2023, 8:30 AM EDT - 2 years ago

Processa Pharmaceuticals Announces First Patient Dosed in the 300 mg Dose Group with Next Generation Chemotherapy-Capecitabine

Mar 7, 2023, 8:30 AM EST - 2 years ago

Processa Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

Feb 21, 2023, 8:30 AM EST - 2 years ago

Processa Pharmaceuticals Announces Prioritization on Development of Next Generation Chemotherapies

Feb 15, 2023, 8:30 AM EST - 2 years ago

Processa Pharmaceuticals, Inc. Announces Closing of $6.25 Million Registered Direct Offering, Which Included Retail Investors and Insiders, Priced at the Market Under Nasdaq Rules

TheDrunkTrader69 Sep. 9 at 8:48 PM

$PCSA Hmmm dead all day an now AH movement

0 · Reply

TheDrunkTrader69 Sep. 9 at 4:00 PM

$PCSA Someone has same thoughts as me buys at .175 just had small add to even out lol.

0 · Reply

Paraplego Sep. 8 at 8:34 PM

0 · Reply

TheDrunkTrader69 Sep. 8 at 8:01 PM

$PCSA This is far from dead and once shorts start getting pummeled you will see this can go from .17 to $1 very quickly .

2 · Reply

Paraplego Sep. 8 at 7:57 PM

$PCSA this is one of those negative people who was talking how pcsa is dead etc doing everything to puah stock value down

0 · Reply

Paraplego Sep. 8 at 7:13 PM

$PCSA i would like to know who is doing this

0 · Reply

jhidle0415 Sep. 8 at 4:19 PM

1 · Reply

red619 Sep. 8 at 1:11 PM

$PCSA pre market is being goofy 0.o

1 · Reply

TheDrunkTrader69 Sep. 8 at 12:47 PM

1 · Reply

TheDrunkTrader69 Sep. 8 at 12:14 PM

1 · Reply

Nvidiagh Sep. 8 at 11:24 AM

$HOOD $PCSA $NEON

0 · Reply

TheDrunkTrader69 Sep. 8 at 10:10 AM

$PCSA not sure about the rest of you but I don't trust Jwa everytime we do anything bullish he is against it but says he has no stakes in the game? Very odd. Sorry of im wrong, its just theres 1 in every stock i trade

2 · Reply

RouletteSpinners Sep. 7 at 11:22 PM

$PCSA float?

1 · Reply

TheDrunkTrader69 Sep. 6 at 9:00 PM

$PCSA Vote NO again

0 · Reply

Goldengun23 Sep. 5 at 8:08 PM

$PCSA Vote NO. To everything proposed. If the company is actually calling investors to vote let them squirm. They’re dumb decisions shouldn’t be at the expense of the shareholders. Figure it tf out

2 · Reply

TheDrunkTrader69 Sep. 5 at 7:03 PM

$PCSA Thank the Lord. Amen 🙏 go baby go.

0 · Reply

TheDrunkTrader69 Sep. 5 at 2:41 PM

$PCSA I started off just flipping profits on the way down, made real good profits, after researching I am now long term with an extremely high share count, feels like its gonna go anyday and hard, as always do your own due diligence, but if this goes to $1 i can retire. Worth it

1 · Reply

Paraplego Sep. 5 at 2:20 PM

$PCSA Imma explain my reasons why i do belive that PCSA will jump 1st they do have enough cash for type of work they are doing 2nd Solid Pipeline that will have sucsess because they are not creating something new they are fixing issues with currently in use meds 3rd good managment if something is not that good they will abandon it and save money 4th 450mil Intact Partnership deal that will become active by end of september possible mid october 5th Stocks are soo cheap right now that even if it gets to 28 cents that is 50%+ Increase on investment 6th PCSA have no issues with intentionall shorting just bunch of afraid people 7th Majority of people sell their stock days/weeks before they hit gold and thats why im holding it so yeah this is my look on this stock and why i do see it growing rapidly soon days or weeks

1 · Reply

Paraplego Sep. 5 at 1:49 PM

$PCSA https://fintel.io/s/us/pcsa

0 · Reply

Paraplego Sep. 5 at 1:47 PM

$PCSA in other words getting stock at this price is a blessing because run can happen at any moment and a lot of people will just skip it

0 · Reply

Paraplego Sep. 5 at 1:46 PM

$PCSA Reason PCSA going down now is because too many people are selling because fear from RS that will happen in few months from now if it happens once all info goes public will RS happen is huge question even after its approved Keep that in mind

0 · Reply

TheDrunkTrader69 Sep. 5 at 11:41 AM

$PCSA

0 · Reply

Market Cap	9.19M
Revenue (ttm)	0.00
Net Income (ttm)	-11.85M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,342,500
Avg Vol	5,779,632
Day's Range	N/A - N/A
Shares Out	50.35M
Stochastic %K	34%
Beta	1.36
Analysts	Sell
Price Target	$1.00